BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368. [PMID: 11996465 DOI: 10.1093/annonc/mdf081] [Cited by in Crossref: 261] [Cited by in F6Publishing: 222] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Sayed MHM, Abdelnaim AK, Mohamadien NR. Intrapatient variability of 18F-FDG uptake in normal tissues. JCIS 2022;12:37. [DOI: 10.25259/jcis_23_2022] [Reference Citation Analysis]
2 Shen DH, Chan HP, Tsai FR, Hu C, Chen AY, Chan HY, Lee CH, Chuang KP, Yang MH, Tyan YC. Prognostic Value of 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Node-Negative Stage II Esophageal Squamous Cell Carcinoma. Metabolites 2021;12:7. [PMID: 35050129 DOI: 10.3390/metabo12010007] [Reference Citation Analysis]
3 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:105. [PMID: 33836789 DOI: 10.1186/s12957-021-02208-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Karmakar S, Mummudi N, Ghosh-Laskar S, Tibdewal A, Kumar R, Patil P, Mehta S, Noronha V, Prabhash K, Purandare N, Pathuthara S, Agarwal JP. Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer. J Gastrointest Cancer 2020. [PMID: 33242151 DOI: 10.1007/s12029-020-00555-0] [Reference Citation Analysis]
5 Radlinski M, Martin LW, Walters DM, Northup P, Wang AY, Rodee T, Sauer BG, Shami VM. Use of endoscopic ultrasound in pre-treatment staging of esophageal cancer did not alter management plan. J Thorac Dis 2020;12:5850-6. [PMID: 33209417 DOI: 10.21037/jtd-20-1299] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Borgstein ABJ, van Berge Henegouwen MI, Lameris W, Eshuis WJ, Gisbertz SS; Dutch Upper GI Cancer Audit. Staging laparoscopy in gastric cancer surgery. A population-based cohort study in patients undergoing gastrectomy with curative intent. Eur J Surg Oncol 2021;47:1441-8. [PMID: 33234483 DOI: 10.1016/j.ejso.2020.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cong E, Oar AJ, Lee MT, Chicco A, Lin M, Yap J, Lin P, Ho Shon I. Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma. J Med Imaging Radiat Oncol 2021;65:23-37. [PMID: 33063470 DOI: 10.1111/1754-9485.13110] [Reference Citation Analysis]
8 Eyck BM, Onstenk BD, Noordman BJ, Nieboer D, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis. Ann Surg 2020;271:245-56. [PMID: 31188203 DOI: 10.1097/SLA.0000000000003397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
9 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Singh S, Bisht N, Sarin A, Kumar AVSA, Gupta S, Kapoor A, Mishra PS. Using positron-emission tomography-computed tomography for predicting radiotherapy-induced tumor regression in carcinoma esophagus in an Indian population. World J Nucl Med 2019;18:361-5. [PMID: 31933551 DOI: 10.4103/wjnm.WJNM_114_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Hernandez JM, Beylergil V, Goldman DA, van Beek E, Gonen M, Tang L, Downey R, Rizk N, Shah M, Strong V, Janjigian Y, Schöder H, Coit DG. Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg 2018;267:898-904. [PMID: 28767564 DOI: 10.1097/SLA.0000000000002306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 de Gouw DJ, Klarenbeek BR, Driessen M, Bouwense SA, van Workum F, Fütterer JJ, Rovers MM, ten Broek RP, Rosman C. Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis. Journal of Thoracic Oncology 2019;14:1156-71. [DOI: 10.1016/j.jtho.2019.04.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
13 Qian D, Wang Y, Zhao G, Cao F, Er P, Chen X, Cheng J, Zhang W, Li X, Zhang B, Guan Y, Zhou D, Wang J, Jiang H, Yu Z, Yuan Z, Wang P, Pang Q. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:319-28. [PMID: 31228553 DOI: 10.1016/j.ijrobp.2019.06.079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Zhang X, Yang Y, Sun Y, Ye B, Guo X, Mao T, Hua R, Li B, Gu H, Liu J, Li Z. Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma. J Thorac Dis 2019;11:2512-22. [PMID: 31372288 DOI: 10.21037/jtd.2019.05.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Dis Esophagus 2018;31. [PMID: 29917073 DOI: 10.1093/dote/doy055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol 2018;41:254-8. [PMID: 26703814 DOI: 10.1097/COC.0000000000000258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Miyake K, Baba Y, Ishimoto T, Hiyoshi Y, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Ogata Y, Nagayama M, Silsirivanit A, Kobayashi D, Araki N, Baba H. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. Med Oncol 2018;36:11. [PMID: 30506321 DOI: 10.1007/s12032-018-1229-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Eyck BM, van der Wilk BJ, Lagarde SM, Wijnhoven BPL, Valkema R, Spaander MCW, Nuyttens JJME, van der Gaast A, van Lanschot JJB. Neoadjuvant chemoradiotherapy for resectable oesophageal cancer. Best Pract Res Clin Gastroenterol 2018;36-37:37-44. [PMID: 30551855 DOI: 10.1016/j.bpg.2018.11.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
19 Yano M, Miyata H, Sugimura K, Motoori M, Omori T, Fujiwara Y, Miyoshi N, Yasui M, Ohue M, Akita H, Tomokuni A, Takahashi H, Kobayashi S, Sakon M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy. Mol Clin Oncol 2018;8:434-40. [PMID: 29456850 DOI: 10.3892/mco.2018.1546] [Reference Citation Analysis]
20 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med 2018;32:165-74. [PMID: 29332233 DOI: 10.1007/s12149-018-1229-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Yap W, Chang Y, Hsieh C, Chao Y, Chen C, Shih M, Hung T. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018;45:689-98. [DOI: 10.1007/s00259-017-3901-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
23 Betancourt Cuellar SL, Palacio DP, Benveniste MF, Carter BW, Hofstetter WL, Marom EM. Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations. Semin Ultrasound CT MR 2017;38:571-83. [PMID: 29179897 DOI: 10.1053/j.sult.2017.07.008] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Ku GY. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical Oncology Clinics of North America 2017;26:241-56. [DOI: 10.1016/j.soc.2016.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Zhang F, Qu J, Zhang H, Liu H, Qin J, Ding Z, Li Y, Ma J, Zhang Z, Wang Z, Zhang J, Zhang S, Dong Y, Grimm R, Kamel IR, Li H. Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol 2017;10:324-31. [PMID: 28327459 DOI: 10.1016/j.tranon.2017.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
26 Kim TH, Kim J, Kang YK, Lee M, Kim HS, Cheon GJ, Chung HH. Identification of Metabolic Biomarkers Using Serial 18F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer. Transl Oncol 2017;10:297-303. [PMID: 28314183 DOI: 10.1016/j.tranon.2017.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Onal C, Torun N, Guler OC, Yildirim BA. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy. Nucl Med Commun 2016;37:1282-9. [PMID: 27612030 DOI: 10.1097/MNM.0000000000000594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
28 Ng SP, Tan J, Osbourne G, Williams L, Bressel MAB, Hicks RJ, Lau EWF, Chu J, Ngan SYK, Leong T. Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Clin Transl Radiat Oncol 2017;2:76-82. [PMID: 29658005 DOI: 10.1016/j.ctro.2017.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Chun SG, Skinner HD, Minsky BD. Radiation Therapy for Locally Advanced Esophageal Cancer. Surg Oncol Clin N Am 2017;26:257-76. [PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
30 Cliffe H, Patel C, Prestwich R, Scarsbrook A. Radiotherapy response evaluation using FDG PET-CT-established and emerging applications. Br J Radiol 2017;90:20160764. [PMID: 28008773 DOI: 10.1259/bjr.20160764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
31 Dewan A, Sharma S, Dewan A, Khurana R, Gupta M, Pahuja A, Srivastava H, Sinha R. Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus. J Gastrointest Canc 2017;48:42-9. [DOI: 10.1007/s12029-016-9870-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
32 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Foley KG, Powell A, Lewis WG, Roberts SA. The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis. Insights Imaging 2016;7:619-28. [PMID: 27278388 DOI: 10.1007/s13244-016-0505-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer 2016;122:2083-90. [PMID: 27152857 DOI: 10.1002/cncr.30028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
35 Yip SS, Coroller TP, Sanford NN, Mamon H, Aerts HJ, Berbeco RI. Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol 2016;6:72. [PMID: 27066454 DOI: 10.3389/fonc.2016.00072] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
36 Hofheinz F, Bütof R, Apostolova I, Zöphel K, Steffen IG, Amthauer H, Kotzerke J, Baumann M, van den Hoff J. An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. EJNMMI Res 2016;6:19. [PMID: 26936768 DOI: 10.1186/s13550-016-0174-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
37 Anderegg MC, de Groof EJ, Gisbertz SS, Bennink RJ, Lagarde SM, Klinkenbijl JH, Dijkgraaf MG, Bergman JJ, Hulshof MC, van Laarhoven HW, van Berge Henegouwen MI. 18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making. PLoS One 2015;10:e0133690. [PMID: 26529313 DOI: 10.1371/journal.pone.0133690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
38 Houshmand S, Boursi B, Salavati A, Simone CB, Alavi A. Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy–related Complications. PET Clinics 2015;10:555-71. [DOI: 10.1016/j.cpet.2015.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
39 Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 2015;51:2545-52. [PMID: 26321501 DOI: 10.1016/j.ejca.2015.07.044] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
40 Schröer-Günther M, Scheibler F, Wolff R, Westwood M, Baumert B, Lange S. The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma. Dtsch Arztebl Int 2015;112:545-52. [PMID: 26356551 DOI: 10.3238/arztebl.2015.0545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
41 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
42 Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015;6:45-52. [PMID: 25642337 DOI: 10.3978/j.issn.2078-6891.2014.054] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
43 Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015;6:53-9. [PMID: 25642338 DOI: 10.3978/j.issn.2078-6891.2014.099] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD. State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol 2015;6:3-19. [PMID: 25642333 DOI: 10.3978/j.issn.2078-6891.2014.062] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
45 Yip C, Cook GJ, Landau DB, Davies A, Goh V. Performance of different imaging modalities in assessment of response to neoadjuvant therapy in primary esophageal cancer. Dis Esophagus 2016;29:116-30. [PMID: 25604614 DOI: 10.1111/dote.12315] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
46 van Rossum P, van Lier A, Lips I, Meijer G, Reerink O, van Vulpen M, Lam M, van Hillegersberg R, Ruurda J. Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clinical Radiology 2015;70:81-95. [DOI: 10.1016/j.crad.2014.07.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
47 Elliott JA, O'farrell NJ, King S, Halpenny D, Malik V, Muldoon C, Johnston C, Reynolds JV. Value of CT–PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma. British Journal of Surgery 2014;101:1702-11. [DOI: 10.1002/bjs.9670] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
48 Park J, Chang KJ, Seo YS, Byun BH, Choi JH, Moon H, Lim I, Kim BI, Choi CW, Lim SM. Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Nucl Med Mol Imaging 2014;48:295-302. [PMID: 26396634 DOI: 10.1007/s13139-014-0289-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
49 Wilson JM, Partridge M, Hawkins M. The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. Clin Oncol (R Coll Radiol) 2014;26:581-96. [PMID: 24998430 DOI: 10.1016/j.clon.2014.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
50 Lloyd S, Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol 2014;5:156-65. [PMID: 24982764 DOI: 10.3978/j.issn.2078-6891.2014.033] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
51 Schollaert P, Crott R, Bertrand C, D'Hondt L, Borght TV, Krug B. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg. 2014;18:894-905. [PMID: 24638928 DOI: 10.1007/s11605-014-2488-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
52 Vera P, Dubray B, Palie O, Buvat I, Hapdey S, Modzelewski R, Benyoucef A, Rousseau C, Meyer ME, Bardet S, Gardin I, Fiore FD, Michel P. Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. EJNMMI Res 2014;4:12. [PMID: 24602385 DOI: 10.1186/2191-219X-4-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
53 Muijs C, Smit J, Karrenbeld A, Beukema J, Mul V, van Dam G, Hospers G, Kluin P, Langendijk J, Plukker J. Residual Tumor After Neoadjuvant Chemoradiation Outside the Radiation Therapy Target Volume: A New Prognostic Factor for Survival in Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 2014;88:845-52. [DOI: 10.1016/j.ijrobp.2013.11.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
54 Metser U, Rashidi F, Moshonov H, Wong R, Knox J, Guindi M, Darling G. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. Ann Nucl Med. 2014;28:295-303. [PMID: 24474598 DOI: 10.1007/s12149-014-0812-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
55 Yuan ST, Brown RK, Zhao L, ten Haken RK, Gross M, Cease KB, Schipper M, Stanton P, Yu J, Kong FM. Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiat Oncol 2014;9:37. [PMID: 24467939 DOI: 10.1186/1748-717X-9-37] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
56 Ku GY, Ilson DH. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 2014;8:1953-64. [DOI: 10.1586/14737140.8.12.1953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hulshoff JB, Smit JK, van der Jagt EJ, Plukker JT. Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients. Am J Surg 2014;208:73-9. [PMID: 24476969 DOI: 10.1016/j.amjsurg.2013.08.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
58 Tsurumaru D, Hiraka K, Komori M, Shioyama Y, Morita M, Honda H. Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy. Radiol Res Pract 2013;2013:502690. [PMID: 24369500 DOI: 10.1155/2013/502690] [Reference Citation Analysis]
59 Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for Esophageal Cancer. Thoracic Surgery Clinics 2013;23:551-8. [DOI: 10.1016/j.thorsurg.2013.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
60 Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumor Response After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer. Annals of Surgery 2013;258:66-76. [DOI: 10.1097/sla.0b013e31828676c4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
61 Kittaka H, Takahashi H, Ohigashi H, Gotoh K, Yamada T, Tomita Y, Hasegawa Y, Yano M, Ishikawa O. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg. 2013;37:169-178. [PMID: 22955953 DOI: 10.1007/s00268-012-1775-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
62 Yoon HJ, Kim SK, Kim TS, Im HJ, Lee ES, Kim HC, Park JW, Chang HJ, Choi HS, Kim DY, Oh JH. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer. Clin Nucl Med. 2013;38:7-12. [PMID: 23242038 DOI: 10.1097/rlu.0b013e3182639a58] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
63 Wu AJ, Goodman KA. Positron emission tomography imaging for gastroesophageal junction tumors. Semin Radiat Oncol. 2013;23:10-15. [PMID: 23207042 DOI: 10.1016/j.semradonc.2012.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
64 Godoy MCB, Bruzzi JF, Viswanathan C, Truong MT, Guimarães MD, Hofstetter WL, Erasmus JJ, Marom EM. Multimodality imaging evaluation of esophageal cancer: staging, therapy assessment, and complications. Abdom Imaging 2013;38:974-93. [DOI: 10.1007/s00261-013-9986-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Atsumi K, Nakamura K, Abe K, Hirakawa M, Shioyama Y, Sasaki T, Baba S, Isoda T, Ohga S, Yoshitake T, Shinoto M, Asai K, Honda H. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res 2013;54:890-8. [PMID: 23520267 DOI: 10.1093/jrr/rrt021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
66 Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol 2013;20:3009-14. [PMID: 23504143 DOI: 10.1245/s10434-013-2946-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
67 van Rossum PS, van Hillegersberg R, Lever FM, Lips IM, van Lier AL, Meijer GJ, van Leeuwen MS, van Vulpen M, Ruurda JP. Imaging strategies in the management of oesophageal cancer: what's the role of MRI? Eur Radiol. 2013;23:1753-1765. [PMID: 23404138 DOI: 10.1007/s00330-013-2773-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
68 Khangura SK, Greenwald BD. Endoscopic Management of Esophageal Cancer After Definitive Chemoradiotherapy. Dig Dis Sci 2013;58:1477-85. [DOI: 10.1007/s10620-012-2554-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
69 Muijs CT, Pruim J, Beukema JC, Berveling MJ, Plukker JT, Langendijk JA. Oesophageal tumour progression between the diagnostic 18F-FDG-PET and the 18F-FDG-PET for radiotherapy treatment planning. Radiother Oncol. 2013;106:283-287. [PMID: 23199654 DOI: 10.1016/j.radonc.2012.10.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
70 Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290-301. [PMID: 23151913 DOI: 10.1007/s00259-012-2280-z] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 11.0] [Reference Citation Analysis]
71 Wang W, Wang K, Chen L. PET Could Predict Response to Neoadjuvant Therapy and Long-Term Survival of Patients with Esophageal Cancer. World J Surg 2013;37:930-1. [DOI: 10.1007/s00268-012-1825-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
73 Yoo C, Park JH, Yoon DH, Park SI, Kim HR, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Kim YH, Kim SB. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg 2012;94:1862-8. [PMID: 22959577 DOI: 10.1016/j.athoracsur.2012.07.042] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
74 Yano M, Motoori M, Tanaka K, Kishi K, Fujiwara Y, Shingai T, Gotoh K, Takahashi H, Noura S, Yamada T, Ohue M, Ohigashi H, Ishikawa O. Preoperative staging of clinically node-negative esophageal cancer by the combination of 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG–PET/CT). Esophagus 2012;9:210-6. [DOI: 10.1007/s10388-012-0342-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
75 Di Fiore F, Blondin V, Hitzel A, Edet-Sanson A, Benyoucef A, Huet E, Vera P, Michel P. 18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma. Dig Liver Dis 2012;44:875-9. [PMID: 22883219 DOI: 10.1016/j.dld.2012.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
76 Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012;23:2638-42. [PMID: 22831985 DOI: 10.1093/annonc/mds210] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
77 Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-welliver M, Konski A. The Role of Qualitative and Quantitative Analysis of F18-FDG Positron Emission Tomography in Predicting Pathologic Response Following Chemoradiotherapy in Patients with Esophageal Carcinoma. J Gastrointest Canc 2012;43:612-8. [DOI: 10.1007/s12029-012-9412-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
78 Abdelsalam M, Bazarbashi S, Abouzied M, Amin T, Soudy H, Rahal M, Darwish A. Whole body 18F-FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: results of a prospective trial. Hematol Oncol Stem Cell Ther 2010;3:179-84. [PMID: 21150237 DOI: 10.5144/1658-3876.2010.179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
79 Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J. The value of <sup>18</sup>F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:171-9. [DOI: 10.5507/bp.2011.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
80 Walrand S, Lhommel R, Goffette P, Van den Eynde M, Pauwels S, Jamar F. Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy. EJNMMI Res 2012;2:20. [PMID: 22608186 DOI: 10.1186/2191-219X-2-20] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
81 Gillies RS, Middleton MR, Blesing C, Patel K, Warner N, Marshall RE, Maynard ND, Bradley KM, Gleeson FV. Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. Eur Radiol 2012;22:2035-43. [PMID: 22562089 DOI: 10.1007/s00330-012-2459-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012;51:636-44. [PMID: 22208782 DOI: 10.3109/0284186X.2011.643822] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
83 Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:471-7. [PMID: 22381904 DOI: 10.1016/j.ijrobp.2011.12.029] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
84 Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, Yu J. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694-e701. [PMID: 22337686 DOI: 10.1259/bjr/29946900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
85 Defoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh. Am J Clin Oncol 2011;34:587-92. [PMID: 22101387 DOI: 10.1097/COC.0b013e3181f942af] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Atway S, Vancourt R. Metastatic esophageal adenocarcinoma of the great toe: a case report. J Foot Ankle Surg 2012;51:205-8. [PMID: 22153295 DOI: 10.1053/j.jfas.2011.10.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 van Heijl M, Phoa S, van Berge Henegouwen M, Omloo J, Mearadji B, Sloof G, Bossuyt P, Hulshof M, Richel D, Bergman J, ten Kate F, Stoker J, van Lanschot J. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. European Journal of Surgical Oncology (EJSO) 2011;37:1064-71. [DOI: 10.1016/j.ejso.2011.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
88 Lordick F, Ott K, Krause BJ. New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol. 2010;21 Suppl 7:vii294-vii299. [PMID: 20943631 DOI: 10.1093/annonc/mdq289] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
89 Blom R, Schreurs W, Belgers H, Oostenbrug L, Vliegen R, Sosef M. The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma. European Journal of Surgical Oncology (EJSO) 2011;37:774-8. [DOI: 10.1016/j.ejso.2011.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
90 Ibeas P, Cantos B, Gasent JM, Rodríguez B, Provencio M. PET-CT in the staging and treatment of non-small-cell lung cancer. Clin Transl Oncol 2011;13:368-77. [DOI: 10.1007/s12094-011-0670-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
91 Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, Corcos L, Visvikis D. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-378. [PMID: 21321270 DOI: 10.2967/jnumed.110.082404] [Cited by in Crossref: 465] [Cited by in F6Publishing: 432] [Article Influence: 42.3] [Reference Citation Analysis]
92 Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Morii E, Mori M, Doki Y. Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer. Annals of Surgery 2011;253:279-84. [DOI: 10.1097/sla.0b013e318206824f] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
93 Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU, Bruewer M. Impact of PET-CT on Primary Staging and Response Control on Multimodal Treatment of Esophageal Cancer. World J Surg 2011;35:608-16. [DOI: 10.1007/s00268-010-0946-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
94 Portwine C, Marriott C, Barr RD. PET imaging for pediatric oncology: an assessment of the evidence. Pediatr Blood Cancer. 2010;55:1048-1061. [PMID: 20979168 DOI: 10.1002/pbc.22747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
95 De Maeseneer DJ, Lambert B, Surmont V, Geboes K, Rottey SW. 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours. Acta Clin Belg 2010;65:291-9. [PMID: 21128554 DOI: 10.1179/acb.2010.065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
96 Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol. 2010;34:465-474. [PMID: 20688444 DOI: 10.1016/j.gcb.2009.04.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
97 Gheysens O, Baete K, Deroose CM, Mottaghy FM. Paramediastinal inflammatory changes after chemoradiation detected on FDG PET-CT imaging. Clin Nucl Med 2010;35:355-6. [PMID: 20395714 DOI: 10.1097/RLU.0b013e3181d626d4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010;254:707-17. [PMID: 20177086 DOI: 10.1148/radiol.09091324] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
99 Makino T, Miyata H, Yamasaki M, Fujiwara Y, Takiguchi S, Nakajima K, Higuchi I, Hatazawa J, Mori M, Doki Y. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Surgery. 2010;148:908-918. [PMID: 20378140 DOI: 10.1016/j.surg.2010.02.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
100 Jingu K, Kaneta T, Nemoto K, Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Takai Y, Takahashi S, Yamada S. 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol 2010;15:184-90. [DOI: 10.1007/s10147-010-0044-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
101 Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 2010;15:270-84. [PMID: 20203174 DOI: 10.1634/theoncologist.2009-0293] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
102 Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894. [PMID: 19953708 DOI: 10.1097/sla.0b013e3181bc9c0d] [Cited by in Crossref: 87] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
103 Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192. [PMID: 19685531 DOI: 10.1002/cncr.24604] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
104 Theisen J, Krause B, Peschel C, Schmid R, Geinitz H, Friess H. Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer. World J Gastrointest Surg 2009; 1(1): 30-37 [PMID: 21160793 DOI: 10.4240/wjgs.v1.i1.30] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
105 Hopkins S, Yang G. Positron emission tomography’s changing significance in the treatment of esophageal cancer. World J Gastrointest Oncol 2009; 1(1): 34-37 [PMID: 21160771 DOI: 10.4251/wjgo.v1.i1.34] [Reference Citation Analysis]
106 Harry VN, Gilbert FJ, Parkin DE. Predicting the response of advanced cervical and ovarian tumors to therapy. Obstet Gynecol Surv 2009;64:548-60. [PMID: 19624866 DOI: 10.1097/OGX.0b013e3181abc114] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
107 Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, Fukuchi M, Oriuchi N, Endo K, Kuwano H. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196-3203. [PMID: 19472406 DOI: 10.1002/cncr.24399] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
108 Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med 2009;39:210-32. [PMID: 19341841 DOI: 10.1053/j.semnuclmed.2008.12.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
109 Ku GY, Ilson DH. Preoperative therapy for esophageal cancer. Gastroenterol Clin North Am 2009;38:135-52, ix. [PMID: 19327572 DOI: 10.1016/j.gtc.2009.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
110 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S. [PMID: 19403881 DOI: 10.2967/jnumed.108.057307] [Cited by in Crossref: 2119] [Cited by in F6Publishing: 1939] [Article Influence: 163.0] [Reference Citation Analysis]
111 Ku GY, Ilson DH. Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. Surgical Oncology Clinics of North America 2009;18:533-46. [DOI: 10.1016/j.soc.2009.03.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
112 Herrmann K, Walch A, Balluff B, Tänzer M, Höfler H, Krause BJ, Schwaiger M, Friess H, Schmid RM, Ebert MP. Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nat Clin Pract Gastroenterol Hepatol. 2009;6:170-183. [PMID: 19259108 DOI: 10.1038/ncpgasthep1366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
113 Ngamruengphong S, Sharma VK, Nguyen B, Das A. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography. Dis Esophagus 2010;23:216-31. [PMID: 19515185 DOI: 10.1111/j.1442-2050.2009.00989.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
114 Jadvar H, Henderson RW, Conti PS. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006;8:193-200. [PMID: 16565910 DOI: 10.1007/s11307-006-0036-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
115 Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM. 18 F-FDG PET and 18 F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer. J Nucl Med 2009;50:89S-96S. [DOI: 10.2967/jnumed.108.057232] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
116 Allen-Auerbach M, Weber WA. Measuring response with FDG-PET: methodological aspects. Oncologist 2009;14:369-77. [PMID: 19357228 DOI: 10.1634/theoncologist.2008-0119] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
117 Salavati A, Basu S, Heidari P, Alavi A. Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nucl Med Commun 2009;30:95-116. [PMID: 19194210 DOI: 10.1097/MNM.0b013e32831af204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
118 Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009;115:624-630. [PMID: 19130466 DOI: 10.1002/cncr.24056] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
119 Suttie SA, Welch AE, Park KG. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. Eur J Surg Oncol 2009;35:1019-29. [PMID: 19232881 DOI: 10.1016/j.ejso.2009.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
120 Brücher BLDM, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Ann Surg Oncol 2009;16:878-86. [DOI: 10.1245/s10434-009-0315-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
121 Schwarz-dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [ 18 F]Fluorodeoxyglucose. JCO 2009;27:535-41. [DOI: 10.1200/jco.2008.17.2650] [Cited by in Crossref: 159] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
122 Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, Bergqvist M. Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 2008;8:1433-48. [PMID: 18759695 DOI: 10.1586/14737140.8.9.1433] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
123 Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET–CT. Radiotherapy and Oncology 2008;89:278-86. [DOI: 10.1016/j.radonc.2008.06.014] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
124 Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH. Response Evaluation by Endoscopy, Rebiopsy, and Endoscopic Ultrasound Does Not Accurately Predict Histopathologic Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. Annals of Surgery 2008;248:902-8. [DOI: 10.1097/sla.0b013e31818f3afb] [Cited by in Crossref: 117] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
125 Hicks RJ. PET for Therapeutic Response Monitoring in Oncology. PET Clin 2008;3:89-99. [PMID: 27158148 DOI: 10.1016/j.cpet.2008.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
126 Garai I, Tóth C, Szabados L, Sóvágó J, Tóth L, Csiki Z. [Metabolic imaging--PET, PET/CT--in oncologic surgery]. Magy Seb 2008;61:217-24. [PMID: 18799405 DOI: 10.1556/MaSeb.61.2008.4.2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Makino T, Doki Y, Miyata H, Yasuda T, Yamasaki M, Fujiwara Y, Takiguchi S, Higuchi I, Hatazawa J, Monden M. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. 2008;144:793-802. [PMID: 19081023 DOI: 10.1016/j.surg.2008.06.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
128 Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA. Metabolic Tumor Width Parameters as Determined on PET/CT Predict Disease-free Survival and Treatment Response in Squamous Cell Carcinoma of the Esophagus. Mol Imaging Biol 2009;11:54-60. [DOI: 10.1007/s11307-008-0169-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
129 Cheze-Le Rest C, Metges JP, Teyton P, Jestin-Le Tallec V, Lozac’h P, Volant A, Visvikis D. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun. 2008;29:628-635. [PMID: 18528185 DOI: 10.1097/mnm.0b013e3282f81423] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
130 Lerut T, Moons J, Coosemans W, Decaluwé H, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Multidisciplinary treatment of advanced cancer of the esophagus and gastroesophageal junction: a European center's approach. Surg Oncol Clin N Am 2008;17:485-502, vii-viii. [PMID: 18486879 DOI: 10.1016/j.soc.2008.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
131 Touboul E, Huguet F, Talbot JN. [Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers]. Cancer Radiother 2008;12:633-9. [PMID: 18693057 DOI: 10.1016/j.canrad.2008.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
132 van Heijl M, Omloo JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Bilgen EJ, Ten Kate FJ, Boellaard R, Pruim J, Sloof GW, van Lanschot JJ. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys 2008;8:3. [PMID: 18671847 DOI: 10.1186/1756-6649-8-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
133 Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57. [PMID: 18626006 DOI: 10.1200/JCO.2007.15.4385] [Cited by in Crossref: 119] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
134 Nakagawa K, Yamashita H, Nakamura N, Igaki H, Tago M, Hosoi Y, Momose T, Ohtomo K, Muto T, Nagawa H. Preoperative Radiation Response Evaluated by 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival in Locally Advanced Rectal Cancer. Diseases of the Colon & Rectum 2008;51:1055-60. [DOI: 10.1007/s10350-008-9243-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
135 Wong WL, Chambers RJ. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review. Abdom Imaging 2008;33:183-90. [PMID: 17619927 DOI: 10.1007/s00261-007-9241-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
136 Saga T, Nakamoto Y, Higashi T, Yoshikawa K. Positron Emission Tomography for the Diagnosis and Management of Patients with Gastrointestinal Malignancies. Gastrointestinal Endoscopy Clinics of North America 2008;18:479-93. [DOI: 10.1016/j.giec.2008.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
137 Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2008;136:205-212, 212.e1-212.e3. [PMID: 18603077 DOI: 10.1016/j.jtcvs.2008.02.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
138 Mcloughlin JM, Melis M, Siegel EM, Dean EM, Weber JM, Chern J, Elliott M, Kelley ST, Karl RC. Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer? Journal of the American College of Surgeons 2008;206:879-86. [DOI: 10.1016/j.jamcollsurg.2007.12.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
139 Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 2008;21:151-8. [DOI: 10.1111/j.1442-2050.2007.00732.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
140 Erasmus JJ, Rohren EM, Hustinx R. PET and PET/CT in the Diagnosis and Staging of Esophageal and Gastric Cancers. PET Clinics 2008;3:135-45. [DOI: 10.1016/j.cpet.2008.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
141 McDonough PB, Jones DR, Shen KR, Northup PG, Galysh RL, Hernandez A, White GE, Kahaleh M, Shami VM. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study. Am J Gastroenterol 2008;103:570-4. [PMID: 17941963 DOI: 10.1111/j.1572-0241.2007.01579.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
142 Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27:1635-1652. [PMID: 18025508 DOI: 10.1148/rg.276065742] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 7.6] [Reference Citation Analysis]
143 Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol). 2008;20:221-226. [PMID: 18248970 DOI: 10.1016/j.clon.2007.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
144 Eary JF. PET imaging for Treatment Response in Cancer. PET Clin 2008;3:101-9. [PMID: 20011618 DOI: 10.1016/j.cpet.2008.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
145 Vinjamuri S, Ray S. Added value of PET and PET–CT in oesophageal cancer: a review of current practice. Nuclear Medicine Communications 2008;29:4-10. [DOI: 10.1097/mnm.0b013e3282f1b9c7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Kostakoglu L. FDG-PET Evaluation of Response to Treatment. PET Clin 2008;3:37-75. [PMID: 27158146 DOI: 10.1016/j.cpet.2008.09.001] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
147 Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med. 2007;21:553-562. [PMID: 18092131 DOI: 10.1007/s12149-007-0040-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
148 Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 2007;7:189-94. [PMID: 18055293 DOI: 10.1102/1470-7330.2007.0027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
149 Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 2007;94:1059-66. [PMID: 17657720 DOI: 10.1002/bjs.5865] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
150 Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. [PMID: 17693134 DOI: 10.2967/jnumed.110.085803] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 8.3] [Reference Citation Analysis]
151 Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. [PMID: 17693134 DOI: 10.1016/s1470-2045(07)70244-9] [Cited by in Crossref: 566] [Cited by in F6Publishing: 202] [Article Influence: 37.7] [Reference Citation Analysis]
152 Rankin SC. Oesophageal cancer: assessment of response and follow up. Cancer Imaging 2007;7 Spec No A:S67-9. [PMID: 17921096 DOI: 10.1102/1470-7330.2007.9019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
153 Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007;30:377-88. [PMID: 17762438 DOI: 10.1097/COC.0b013e31803993f8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
154 Basu S, Alavi A. Staging with PET and the “Will Rogers” effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging 2008;35:1-4. [DOI: 10.1007/s00259-007-0506-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
155 Chang EY, Li X, Jerosch-Herold M, Priest RA, Enestvedt CK, Xu J, Springer CS, Jobe BA. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12:166-175. [PMID: 17768665 DOI: 10.1007/s11605-007-0253-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
156 Gillham CM, Reynolds J, Hollywood D. Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World J Surg Oncol 2007;5:97. [PMID: 17716369 DOI: 10.1186/1477-7819-5-97] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
157 Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932. [PMID: 17680242 DOI: 10.1007/s00259-007-0521-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
158 Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2007;2:553-568. [PMID: 17545853 DOI: 10.1097/01.JTO.0000275339.62831.5e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
159 Sloof GW. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol. 2006;20:941-957. [PMID: 16997171 DOI: 10.1016/j.bpg.2006.04.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
160 Kim MK, Ryu J, Kim S, Ahn JH, Kim SY, Park S, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho K, Kim JH. Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. European Journal of Cancer 2007;43:1385-91. [DOI: 10.1016/j.ejca.2007.04.001] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
161 Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:358-63. [PMID: 17532577 DOI: 10.1016/j.ijrobp.2007.03.053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
162 Westerterp M, Van Westreenen HL, Sloof GW, Plukker JT, Van Lanschot JJ. Role of positron emission tomography in the (re-)staging of oesophageal cancer. Scand J Gastroenterol Suppl 2006;:116-22. [PMID: 16782630 DOI: 10.1080/00365520600664409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
163 Wood KA, Hoskin PJ, Saunders MI. Positron emission tomography in oncology: a review. Clin Oncol (R Coll Radiol) 2007;19:237-55. [PMID: 17433969 DOI: 10.1016/j.clon.2007.02.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
164 Erasmus JJ, Munden RF. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol. 2007;17:29-37. [PMID: 17185195 DOI: 10.1016/j.semradonc.2006.09.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
165 Eschmann S, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Dittmann H, Langen H, Bares R. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007;55:165-71. [DOI: 10.1016/j.lungcan.2006.09.028] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
166 Wieder H, Herrmann K, Krause B. 18F-FDG-PET zur Therapieverlaufskontrolle beim Ösophaguskarzinom. Radiologe 2007;47:110-4. [DOI: 10.1007/s00117-006-1461-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
167 Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007;109:125-34. [DOI: 10.1002/cncr.22397] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
168 Ott K, Weber W, Siewert J. The importance of Pet in the diagnosis and response evaluation of esophageal cancer. Diseases of the Esophagus 2006;19:433-42. [DOI: 10.1111/j.1442-2050.2006.00617.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
169 Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'byrne K, Hollywood D, Muldoon C, Reynolds JV. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9. [PMID: 17024121 DOI: 10.1038/sj.bjc.6603412] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
170 Ilson DH. Cancer of the gastroesophageal junction: Current therapy options. Curr Treat Options in Oncol 2006;7:410-23. [DOI: 10.1007/s11864-006-0009-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
171 Ilson DH. Cancer of the Gastroesophageal Junction: Combined Modality Therapy. Surgical Oncology Clinics of North America 2006;15:803-24. [DOI: 10.1016/j.soc.2006.07.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
172 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
173 Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, Ferris RL, Avril N. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315-1322. [PMID: 16750327 DOI: 10.1016/j.ijrobp.2006.03.015] [Cited by in Crossref: 130] [Cited by in F6Publishing: 104] [Article Influence: 8.1] [Reference Citation Analysis]
174 Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu T, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging: . Journal of Thoracic Oncology 2006;1:478-86. [DOI: 10.1097/01243894-200606000-00016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
175 Everitt C, Leong T. Influence of 18F-fluorodeoxyglucose-positron emission tomography on computed tomography-based radiation treatment planning for oesophageal cancer. Australas Radiol 2006;50:271-4. [DOI: 10.1111/j.1440-1673.2006.01578.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
176 Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Diseases of the Esophagus 2006;19:158-63. [DOI: 10.1111/j.1442-2050.2006.00558.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
177 Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu T, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. Journal of Thoracic Oncology 2006;1:478-86. [DOI: 10.1016/s1556-0864(15)31614-2] [Cited by in Crossref: 21] [Article Influence: 1.3] [Reference Citation Analysis]
178 Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478. [PMID: 16552197 DOI: 10.1097/01.sla.0000208430.07050.61] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 7.8] [Reference Citation Analysis]
179 Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33:27-37. [DOI: 10.1007/s00259-006-0133-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
180 Munden RF, Macapinlac HA, Erasmus JJ. Esophageal Cancer: The Role of Integrated CT-PET in Initial Staging and Response Assessment After Preoperative Therapy: . Journal of Thoracic Imaging 2006;21:137-45. [DOI: 10.1097/00005382-200605000-00005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
181 Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, Thomas RJ. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:770-8. [PMID: 16550384 DOI: 10.1007/s00259-005-0040-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
182 Chin BB, Chang PP. Gastrointestinal malignancies evaluated with 18F-fluoro-2-deoxyglucose positron emission tomography. Best Practice & Research Clinical Gastroenterology 2006;20:3-21. [DOI: 10.1016/j.bpg.2005.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
183 Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005;104:1620-1626. [PMID: 16118804 DOI: 10.1002/cncr.21356] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.3] [Reference Citation Analysis]
184 Bosset JF, Lorchel F, Mantion G, Buffet J, Créhange G, Bosset M, Chaigneau L, Servagi S. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:239-45. [PMID: 16299784 DOI: 10.1002/jso.20365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
185 Forshaw M, Gossage J, Mason R. Neoadjuvant chemotherapy for oesophageal cancer: The need for accurate response prediction and evaluation. The Surgeon 2005;3:373-82. [DOI: 10.1016/s1479-666x(05)80047-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
186 Lordick F. Neoadjuvante Therapie von Plattenepithelkarzinomen des Ösophagus: Was ist „evidence based“? Chirurg 2005;76:1025-32. [DOI: 10.1007/s00104-005-1098-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
187 Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song H, Cho K, Ahn SD, Lee S, Shin SS, Choi EK. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. International Journal of Radiation Oncology*Biology*Physics 2005;63:1053-9. [DOI: 10.1016/j.ijrobp.2005.03.033] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 5.6] [Reference Citation Analysis]
188 Weber WA. PET for response assessment in oncology: radiotherapy and chemotherapy. BJR 2005;Supplement_28:42-9. [DOI: 10.1259/bjr/59640473] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
189 Grosu AL, Wiedenmann N, Molls M. Biological imaging in radiation oncology. Z Med Phys 2005;15:141-5. [PMID: 16171034 DOI: 10.1078/0939-3889-00264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
190 Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. Radiology. 2005;236:841-851. [PMID: 16118165 DOI: 10.1148/radiol.2363041042] [Cited by in Crossref: 207] [Cited by in F6Publishing: 175] [Article Influence: 12.2] [Reference Citation Analysis]
191 Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Kuwano H. Positron emission tomography in esophageal cancer. Esophagus 2005;2:111-21. [DOI: 10.1007/s10388-005-0053-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
192 Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53. [PMID: 16157939 DOI: 10.1200/JCO.2005.06.965] [Cited by in Crossref: 201] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
193 Bedenne L. [Chemoradiation: an alternative to surgery for the curative treatment esophageal cancer?]. Gastroenterol Clin Biol 2005;29:551-6. [PMID: 15980749 DOI: 10.1016/s0399-8320(05)82127-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-60; discussion 1152-60. [PMID: 15464463 DOI: 10.1016/j.athoracsur.2004.04.046] [Cited by in Crossref: 216] [Cited by in F6Publishing: 194] [Article Influence: 12.7] [Reference Citation Analysis]
195 Yen R, Chen TH, Ting L, Tzen K, Pan M, Hong R. Early restaging whole-body 18F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1152-9. [DOI: 10.1007/s00259-005-1837-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
196 Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005;35:316-323. [PMID: 15961436 DOI: 10.1093/jjco/hyi095] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.2] [Reference Citation Analysis]
197 Aberle DR, Chiles C, Gatsonis C, Hillman BJ, Johnson CD, Mcclennan BL, Mitchell DG, Pisano ED, Schnall MD, Sorensen AG. Imaging and Cancer: Research Strategy of the American College of Radiology Imaging Network. Radiology 2005;235:741-51. [DOI: 10.1148/radiol.2353041760] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
198 Bar-shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, Ben-nun A, Keidar Z, Israel O. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005;32:918-24. [DOI: 10.1007/s00259-005-1795-y] [Cited by in Crossref: 91] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
199 Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, Hiele M, Flamen P. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol. 2004;73:269-275. [PMID: 15588870 DOI: 10.1016/j.radonc.2004.10.001] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
200 Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337. [PMID: 15781882 DOI: 10.1200/jco.2005.05.017] [Cited by in Crossref: 324] [Cited by in F6Publishing: 129] [Article Influence: 19.1] [Reference Citation Analysis]
201 Meerten EV, van der Gaast A. Systemic treatment for oesophageal cancer. European Journal of Cancer 2005;41:664-72. [DOI: 10.1016/j.ejca.2004.10.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
202 Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189-204. [PMID: 15693656 DOI: 10.1016/j.rcl.2004.09.006] [Cited by in Crossref: 123] [Cited by in F6Publishing: 103] [Article Influence: 7.2] [Reference Citation Analysis]
203 Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, Adler L. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. International Journal of Radiation Oncology*Biology*Physics 2005;61:1123-8. [DOI: 10.1016/j.ijrobp.2004.07.717] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
204 Detterbeck FC, Vansteenkiste JF, Morris DE, Dooms CA, Khandani AH, Socinski MA. Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. Chest 2004;126:1656-66. [PMID: 15539740 DOI: 10.1378/chest.126.5.1656] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
205 Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103:148-156. [PMID: 15558794 DOI: 10.1002/cncr.20724] [Cited by in Crossref: 171] [Cited by in F6Publishing: 132] [Article Influence: 10.1] [Reference Citation Analysis]
206 Castillo E, Lawler LP. Diagnostic radiology and nuclear medicine. J Surg Oncol 2005;92:191-202. [DOI: 10.1002/jso.20360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
207 Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiologic Clinics of North America 2004;42:1123-39. [DOI: 10.1016/j.rcl.2004.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
208 Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 2004;91:1004-9. [PMID: 15286962 DOI: 10.1002/bjs.4595] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
209 Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199:1-7. [PMID: 15217621 DOI: 10.1016/j.jamcollsurg.2004.02.024] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 8.1] [Reference Citation Analysis]
210 Flamen P. Positron emission tomography in gastric and esophageal cancer: . Current Opinion in Oncology 2004;16:359-63. [DOI: 10.1097/01.cco.0000128276.13585.fa] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
211 Brink I, Hentschel M, Bley T, Walch A, Mix M, Kleimaier M, Moser E, Imdahl A. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. European Journal of Surgical Oncology (EJSO) 2004;30:544-50. [DOI: 10.1016/j.ejso.2004.03.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
212 Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M. Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Diseases of the Esophagus 2004;17:129-35. [DOI: 10.1111/j.1442-2050.2004.00389.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
213 Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908. [PMID: 14990646 DOI: 10.1200/jco.2004.07.122] [Cited by in Crossref: 340] [Cited by in F6Publishing: 105] [Article Influence: 18.9] [Reference Citation Analysis]
214 Berger AC, Scott WJ. Noninvasive staging of esophageal carcinoma. Journal of Surgical Research 2004;117:127-33. [DOI: 10.1016/j.jss.2003.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
215 Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91:199-204. [PMID: 14760668 DOI: 10.1002/bjs.4411] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
216 Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;57:1328-1335. [PMID: 14630270 DOI: 10.1016/s0360-3016(03)00751-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
217 Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert J, Weber WA. Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial. JCO 2003;21:4604-10. [DOI: 10.1200/jco.2003.06.574] [Cited by in Crossref: 250] [Cited by in F6Publishing: 84] [Article Influence: 13.2] [Reference Citation Analysis]
218 Annovazzi A, Peeters M, Maenhout A, Signore A, Dierckx R, Van De Wiele C. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003;125:1235-45. [PMID: 14517805 DOI: 10.1016/s0016-5085(03)01208-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
219 Hermans R. Imaging of hypopharyngeal and cervical oesophageal cancer. Cancer Imaging 2003;4:7-9. [PMID: 18211853 DOI: 10.1102/1470-7330.2003.0025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
220 Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657. [PMID: 12860940 DOI: 10.1200/jco.2003.12.004] [Cited by in Crossref: 388] [Cited by in F6Publishing: 108] [Article Influence: 20.4] [Reference Citation Analysis]
221 von Rahden BHA, Stein HJ, Siewert JR. Barrett’s esophagus and Barrett’s carcinoma. Curr Oncol Rep 2003;5:203-9. [DOI: 10.1007/s11912-003-0111-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
222 Solomon B, Mcarthur GA, Cullinane C, Zalcberg JR, Hicks RJ. Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics: . BioDrugs 2003;17:339-54. [DOI: 10.2165/00063030-200317050-00004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
223 Laking G, Price P. FDG-PET for response assessment: answers in search of questions. Annals of Oncology 2002;13:345-7. [DOI: 10.1093/annonc/mdf144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Brücher BL, Keller G, Werner M, Müller U, Lassmann S, Cabras AD, Fend F, Busch R, Stein H, Allescher HD. Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis. 2009;24:69-77. [PMID: 738222 DOI: 10.1007/s00384-008-0562-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.3] [Reference Citation Analysis]